The Risk of recurrence in prostate cancer
by: Fritz Frei
Prostate cancer disease
Prostate cancer - the most common form of cancer in men is Prostate cancer, the second leading cause of cancer death. The Main risk factors include age (incidence increases in men over the age of 65 years). It is more prevalent in the western world and about 10% of cases can be linked to family history. The recurrance Rate of the prostate cancer is high.
Mostly, the Prostate cancer is a continuum; progressing through localized, locally advanced, advanced and hormone-refractory stages In general it is a slow growing cancer. He is primarily under hormonal control i.e. testosterone. The choice of treatments which include watchful waiting, surgery (prostatectomy), radiotherapy, hormonal therapy and chemotherapy are dependent on the stage of disease.
1. Most important, that If detected early, using PSA determination, DRE examination and biopsies, and treated appropriately, survival rates are excellent.
2. The most critical focus for the treatment of prostate cancer is to treat those cancers where it is necessary.
3. The Decisions about the best management of prostate cancer can be very complex and depend upon the:
- Pathology of the cancer (unlike other cancers, prostate cancer often progresses very slowly)
- The impact that treatment can have on quality of life, including sexual activity
- Stage of the disease (non-metastatic (localized or locally advanced), metastatic or hormone refractory)
- Age and general health of the patients at diagnosis
- Patient’s preference for treatment
- PSA at diagnosis
4. The treatment options for prostate cancer are:
- Deferred treatment often called ‘watchful waiting’ or 'active surveillance'
- Surgery – Radical Prostatectomy
- Radiotherapy – External Beam and/or Brachytherapy
-Hormonal (endocrine) therapy – Androgen Ablation e.g. anti-androgens, medical castration (LHRHa) or surgical castration
- Palliative Therapy e.g. chemotherapy
- Investigational Therapies
Prostate Cancer Recurrence Rates ***
Prostate cancer is now detected at earlier stages due to heightened awareness and improved screening techniques. Despite definitive therapy, cancer cells may remain and can go undetected for years until they develop into metastatic disease. The risk of recurrence is high, suggesting there is a need to improve treatment approaches. Therefore, it is important to predict pathological stage and risk of disease recurrence early, so that appropriate treatment and/or monitoring can be initiated. The result's of all new treatments will bring us in the future the chance of a lower prostate recurrance.
**You can inform you about the recurrence Rates on:
This gives you an overview with a study case – and the results.
Latest Cancer News:
Pfizer to test Xalkori lung cancer drug with Merck immunotherapy
Pfizer Inc said Tuesday it will test its Xalkori lung cancer drug with Merck & Co's experimental immunotherapy pembrolizumab, in hopes the combination will improve the outcomes for patients taking the approved Pfizer therapy. Xalkori, which has annual sales of $400 million and is also known by its chemical name, crizotinib, was approved in 2011 for lung cancer patients who have a specific ... Global Cancer Diagnostics Announces Start of Final Validation Study for Its New Blood Test for the Early Detection of ...
Global Cancer Diagnostics Inc. today announced the start of the final validation study of its new blood test for early detection of lung cancer. The study will complete the requisite analyses and data evaluation needed to validate the test and introduce it to the market. Cancer Genetics' Proprietary Genomic Diagnostic Tests Added to National Institutes of Health's Genetic Testing Registry
RUTHERFORD, N.J. -- Cancer Genetics, Inc. ("CGI" or "The Company"), an emerging leader in DNA-based cancer diagnostics, announced today that the National Institutes of Health's (NIH) ... 10 questions to ask your doctor after a cancer diagnosis
Whether you have cancer or someone close to you does, there are some basic facts to understand about the diagnosis in order to begin moving forward with a treatment program New research details rare cancer that killed Bob Marley
Brooks Hays MANCHESTER, England, Aug. 20 (UPI) -- Acral melanomas -- a rare form of skin cancer and the type that claimed the life of reggae musician Bob Marley -- are genetically distinct. Ten Questions to Ask Your Doctor After a Cancer Diagnosis
Dr. Bavesh Balar is a board-certified hematologist and oncologist on staff at CentraState Medical Center in Freehold, N.J., where he serves as chairman of the Cancer Committee. The healthcare community has made remarkable strides over the past 20 years in treating cancer, but more than a million people in the United States are still diagnosed every year. As devastating as that news is, whether ... Pfizer to Test Lung Cancer Drug with Immunotherapy
Pfizer Inc said Tuesday it will test its Xalkori lung cancer drug with Merck & Co's experimental immunotherapy pembrolizumab, in the hopes the combination will improve the outcomes for patients taking the approved Pfizer therapy. Exclusive: U.S. approval of Merck cancer immunotherapy expected soon
If approved by the Food and Drug Administration, the drug would be the first in a promising new class designed to help the body's own immune system fend off cancer by blocking a protein known as Programmed Death receptor (PD-1), or a related target known as PD-L1, used by tumors to evade disease-fighting cells. Companies including Bristol-Myers Squibb, Roche Holding AG and AstraZeneca Plc are ... Medicaid payouts for office visits may influence cancer screening: study
By Kathryn Doyle NEW YORK (Reuters Health) ? In states where Medicaid pays doctors higher fees for office visits, Medicaid beneficiaries are more likely to be screened for breast, cervical or colorectal cancer, according to a new study. ?States tend to vary in their reimbursement rates for different types of medical care services; Each state establishes its own coverage and reimbursement policies. NextGen Healthcare Earns 2014 ONC HIT Cancer Registry Certification
NextGen Healthcare Information Systems, LLC., a wholly owned subsidiary of Quality Systems, Inc. and a leading provider of healthcare information systems and connectivity solutions, announced today NextGen® Ambulatory EHR version 5.8.1 is compliant with the ONC 2014 Edition criteria for certification measures 170.314 , Cancer Case Information, and 170.314 , Transmission to Cancer Registries ... NY1 anchor Roma Torre has colon cancer - New York Post